New Data Demonstrate Efficacy and Tolerabilty of Bystolic® (Nebivolol) Tablets among Hispanics with Hypertension
May 03 2010 - 6:13PM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX) today presented data from
a Phase IV study evaluating the effects of Bystolic® (nebivolol)
tablets in Hispanic patients with hypertension at the 2010 annual
scientific meeting of the American Society of Hypertension (ASH).
Results showed Bystolic significantly reduced sitting systolic
(p=0.001) and diastolic (p
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024
